As per available reports about 89 journals, 72 Conferences, 9 workshops are presently dedicated exclusively to Chronic Myeloid Leukaemia and about 203,000 articles are being published on the current trends in Chronic Myeloid Leukaemia. In terms of research annually, USA, India, Japan, Brazil and Canada are some of the leading countries where maximum studies related to Chronic Myeloid Leukaemia are being carried out. As reported in American Cancer Society, Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. In CML, leukemia cells tend to build up in the body over time, but many people don't have any symptoms for at least a few years. In time, the cells can also invade other parts of the body, including the spleen. Chronic myeloid leukemia can also change into a fast-growing acute leukemia that invades almost any organ in the body.
Journal of Cancer Science & Therapy is an academic journal – hosted by OMICS International – a pioneer in open access publishing–and is listed among the top 10 journals in Chronic Myeloid Leukaemia. Each year research scientists have noticed a rise in the number of congresses being held in this field. Journal of Cancer Science & Therapy provides a unique platform to researchers and scientist to explore the advanced and latest research developments in the field of Chronic Myeloid Leukaemia and related fields, thus bridging the gap between researchers and young scientists.
OMICS International is a pioneer in organizing international conferences. The conference related to Chronic Myeloid Leukaemia is Conference on Cancer Science & Therapy. The scientific sessions of the Cancer Science conferences housing the current research in cancer research. Tumor science will host presentations related to Tumor Microenvironment, communication, and Tumor progression. Cancer therapeutics will focus on translating cancer biology research into novel oncology treatments. Cancer imaging, Cancer cell biology session revolves around molecular basis of cancer and treatments for this devastating disease Drug discovery and development, Molecular cancer biology, and Transcriptomics and more. The main objective of the Cancer Science conferences is to broaden the scope of meeting by hosting sessions on new developments.
|Our Group hosts over 700 leading-edge peer reviewed Open Access Journals and organize over 3000 International Conferences annually all over the world. Our Group journals have over 3 million readers and the fame and success of the same can be attributed to the strong editorial board which contains over 50000 eminent personalities that ensure a rapid, quality and quick review process. Our Group signed an agreement with more than 1000 International Societies to make healthcare information Open Access.
List of major Chronic Myeloid Leukaemia and related journals
• Journal of Cancer Science & Therapy
• Integrative Oncology
• Carcinogenesis & Mutagenesis
• Chemotherapy: Open Access
• Blood Cancer Journal
• Cancer Cell
• Journal of the National Cancer Institute
• Clinical Cancer Research
• Annals of Oncology
• Blood Reviews
List of major Chronic Myeloid Leukaemia related Conferences
• World Congress on Cancer Science & Therapy
• Clinical Hematology and Oncology 2015: The 12th Annual Mayo Review
• International Conference on Hematology & Blood Disorders 2015
• Annual Mayo Clinic Hematology/Oncology Reviews
• Society for Hematology and Stem Cells - ISEH 43rd Annual Scientific Meeting 2015
• World Congress on Controversies in Hematology (COHEM 2015)
List of major Chronic Myeloid Leukaemia related Research Centres
• National Cancer Institute
• Fred Hutchinson Cancer Research Center
• Stanford Research Institute (SRI) International
• Chronic myelogenous leukemia - Mayo Clinic
• Cancer Research UK
List of major Chronic Myeloid Leukaemia related Socities
• American Cancer Society
• Swedish Cancer Society
• Cancer Society of New Zealand
• The Humane Society
|This page will be updated regularly.
This page was last updated on May 18, 2022